Mechera Robert, Schuster Tibor, Rosenberg Robert, Speich Benjamin
Department of Surgery, Cantonal Hospital Baselland, Liestal, Switzerland; Department of Surgery, University Hospital of Basel, Basel, Switzerland.
Department of Family Medicine, McGill University, Montreal, Quebec, Canada.
Eur J Cancer. 2017 Feb;72:84-94. doi: 10.1016/j.ejca.2016.10.031. Epub 2016 Dec 24.
The lymph node status represents a major prognostic factor in colorectal cancer. However, it was demonstrated that neoadjuvant chemoradiotherapy (CRT) decreases the numbers of lymph nodes in the specimen. Several studies describe less than 12 lymph nodes in the resected specimen of rectal cancer patients after neoadjuvant radiation. This meta-analysis quantifies the influence of neoadjuvant CRT or radiotherapy (RT) only on the lymph node yield in rectal cancer patients.
We performed a systematic review and searched PubMed, EMBASE and the Cochrane Library without any language restriction from 1st of January 1980 until 31st March 2015. Two reviewers examined all publications independently and extracted the relevant data if the study assessed lymph node counts or positive lymph node yields of patients who received neoadjuvant treatment compared with patients who did not receive neoadjuvant treatment. Meta-analyses were conducted to quantify the mean difference in lymph node yield.
A total of 34 articles (including 37 datasets) were included in the meta-analyses. Neoadjuvant CRT resulted in a mean reduction of 3.9 lymph nodes (95% confidence interval [CI] 3.7-4.1) and an average reduction in harvested positive lymph nodes of 0.7 (95% CI 0.2-1.2) compared with patients who received no neoadjuvant therapy. Individuals who received neoadjuvant RT had, in average, 2.1 lymph node less (95% CI 1.7-2.5) resected compared with their counterparts who received no neoadjuvant treatment.
Neoadjuvant CRT or RT only in rectal cancer patients leads to a decrease in lymph node harvest of approximately four and two lymph nodes, respectively. We therefore stress the importance of intensifying all efforts from involved subspecialities (i.e. surgeons and pathologists) to reach the benchmark harvest of 12 resected lymph nodes according to current guidelines.
淋巴结状态是结直肠癌的一个主要预后因素。然而,有研究表明新辅助放化疗(CRT)会减少标本中的淋巴结数量。多项研究描述了新辅助放疗后直肠癌患者切除标本中的淋巴结少于12个。本荟萃分析旨在量化新辅助CRT或放疗(RT)仅对直肠癌患者淋巴结获取量的影响。
我们进行了一项系统综述,检索了1980年1月1日至2015年3月31日期间的PubMed、EMBASE和Cochrane图书馆,无任何语言限制。两名评审员独立检查所有出版物,并提取相关数据,前提是该研究评估了接受新辅助治疗的患者与未接受新辅助治疗的患者的淋巴结计数或阳性淋巴结获取量。进行荟萃分析以量化淋巴结获取量的平均差异。
荟萃分析共纳入34篇文章(包括37个数据集)。与未接受新辅助治疗的患者相比,新辅助CRT导致平均淋巴结减少3.9个(95%置信区间[CI] 3.7 - 4.1),获取的阳性淋巴结平均减少0.7个(95% CI 0.2 - 1.2)。与未接受新辅助治疗的患者相比,接受新辅助RT的个体平均切除的淋巴结少2.1个(95% CI 1.7 - 2.5)。
仅对直肠癌患者进行新辅助CRT或RT分别导致淋巴结获取量减少约4个和2个。因此,我们强调各相关亚专业(即外科医生和病理学家)加大所有努力以达到当前指南规定的切除12个淋巴结的基准获取量至关重要。